AEROSPAN HFA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AEROSPAN HFA (AEROSPAN HFA).
Corticosteroid that binds to glucocorticoid receptors, leading to inhibition of inflammatory mediators such as cytokines and phospholipase A2, and suppression of airway inflammation.
| Metabolism | Primarily hepatic via CYP3A4; also esterase-mediated hydrolysis to inactive metabolites. |
| Excretion | Renal excretion of metabolites (approximately 60-80%) and fecal elimination (approximately 12-24%). Unchanged drug is minimally excreted in urine (<1%). |
| Half-life | Terminal elimination half-life is approximately 1.5-2 hours after inhalation. This short half-life is consistent with rapid systemic clearance and supports twice-daily dosing for maintenance therapy. |
| Protein binding | Approximately 87-90% bound to plasma proteins, primarily albumin. Binding is reversible and non-saturable. |
| Volume of Distribution | Volume of distribution at steady-state (Vdss) is 4-5 L/kg after intravenous administration, indicating extensive tissue distribution into the lungs and peripheral tissues. |
| Bioavailability | Oral bioavailability is approximately 11% due to extensive first-pass metabolism. Inhaled bioavailability is significantly higher, with about 30-40% of the inhaled dose reaching systemic circulation. |
| Onset of Action | Onset of bronchodilator effect is within 15-30 minutes after inhalation. Maximal improvement in FEV1 is observed within 4-6 hours. |
| Duration of Action | Duration of bronchodilator effect is 8-12 hours in most patients. Once-daily dosing provides sustained effect, though maximal duration may be longer with regular use. |
2 inhalations (160 mcg/flumetasone pivalate equivalent) twice daily by oral inhalation.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment recommended for mild to moderate hepatic impairment. For severe hepatic impairment (Child-Pugh class C), dose should be reduced to the lowest effective dose. |
| Pediatric use | Children 4-11 years: 2 inhalations (80 mcg) twice daily. Children 12 years and older: same as adult. |
| Geriatric use | No specific dosage adjustment; use lowest effective dose due to potential increased systemic sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AEROSPAN HFA (AEROSPAN HFA).
| Breastfeeding | No published human data; M/P ratio unknown. Inhaled corticosteroids have minimal systemic absorption; unlikely to cause adverse effects in breastfed infant. Use with caution. |
| Teratogenic Risk | Insufficient human data; animal studies show no teratogenic effects at clinically relevant doses. Considered low risk; use only if benefit outweighs risk, especially during first trimester. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Primary treatment of status asthmaticus or acute asthma exacerbations","Hypersensitivity to any component"]
| Precautions | ["May cause local oropharyngeal fungal infections","Adrenal insufficiency during stress or withdrawal","Reduced growth velocity in children","Increased intraocular pressure and glaucoma","Systemic corticosteroid effects with high doses"] |
| Food/Dietary | No specific dietary restrictions. Avoid grapefruit juice as it may increase systemic exposure of flunisolide. Maintain adequate calcium and vitamin D intake to prevent ICS-associated bone loss. |
Loading safety data…
| Monitor maternal asthma control and lung function; assess for adrenal suppression with prolonged high-dose use; fetal growth and well-being via ultrasound if indicated. |
| Fertility Effects | No known adverse effects on fertility in animal or human studies. |
| Clinical Pearls |
| AEROSPAN HFA (flunisolide) is an inhaled corticosteroid (ICS) for maintenance treatment of asthma, not for acute bronchospasm. Prime the inhaler before first use or if not used for >7 days. Rinse mouth after each use to prevent oral candidiasis and hoarseness. Dose adjustment may be needed in patients switching from oral corticosteroids. Monitor for adrenal insufficiency during stress or surgery. May reduce growth velocity in children; monitor height periodically. |
| Patient Advice | Use AEROSPAN HFA regularly as prescribed, not for sudden breathing problems. · Prime the inhaler by shaking well and spraying 4 test sprays into the air away from face before first use or if not used for more than 7 days. · Rinse your mouth with water after each use to prevent thrush or hoarseness. · Do not stop using this medication suddenly; follow your doctor's instructions to taper if needed. · Keep a rescue inhaler (e.g., albuterol) available for acute asthma attacks. · Store the inhaler at room temperature away from heat and open flames; do not puncture or burn. · Inform your doctor if you have been exposed to chickenpox or measles, or if you have any signs of infection. |